One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Role for Artificial Intelligence in the Detection of Immune-Related Adverse Events
doi : 10.1200/JCO-24-01570
2024, Volume 42 (35)
Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201
doi : 10.1200/JCO.24.00709
Human Epidermal Growth Factor Receptor 2 Pan Tumor Indication for Trastuzumab Deruxtecan
doi : 10.1200/JCO.24.00884
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records
doi : 10.1200/JCO.24.00326
Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs
doi : 10.1200/JCO.24.00349
Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis
doi : 10.1200/JCO.24.00332
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors
doi : 10.1200/JCO.23.02229
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
doi : 10.1200/JCO.23.02733
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
doi : 10.1200/JCO.24.00394
First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer
doi : 10.1200/JCO.24.00576
Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
doi : 10.1200/JCO.24.00381
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma
doi : 10.1200/JCO.23.01867
Improving Assessment of Radiorecurrent Prostate Cancer: Implications for Salvage Reirradiation
doi : 10.1200/JCO.24.01067
Erratum: Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies
doi : 10.1200/JCO-24-02370
Erratum: Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma
doi : 10.1200/JCO-24-02371
